Adaptyv Raises €34.35M Series A

Lausanne-based Adaptyv, a biotech startup building an automated wet lab for AI-driven protein design, has secured €34.35 million in Series A funding. The company, which specializes in bridging the gap between digital protein design and physical validation, plans to use the new capital to scale its lab operations and expand its research capabilities.

Investors

The round was led by Highland Europe, with participation from existing investors Ace Ventures, ByFounders, and Y Combinator.

Adaptyv Use of Funds

The company plans to use the funding for horizontal expansion of lab capacity, including opening a new facility in London and expanding its Lausanne base. It also intends to move vertically into harder biology problems, including developability and full biophysical characterization, and next-generation modalities such as peptides, ADCs, and degraders.

About Adaptyv

Founded in 2024 by Julian Englert and Daniel Nakhaee-Zadeh Gutierrez, Adaptyv provides an automated, AI-native lab environment. The platform allows users to submit protein designs through a web interface or API, facilitating automated synthesis, expression, and experimental testing to provide real-world proof for AI-driven drug discovery.

Funding Details

Company Website: https://adaptyvbio.com

Company: Adaptyv
Raised: €34.35M
Round: Series A
Funding Date: August 2026
Lead Investor: Highland Europe
Additional Investors: Ace Ventures, ByFounders, Y Combinator
Software Category: Biotech
Source: https://www.eu-startups.com/2026/08/lausanne-based-adaptyv-raises-e34-35-million-series-a-to-build-the-automated-lab-for-agentic-biology/